Cadila Healthcare

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of

The domestic stock markets are expected to trade cautiously on Thursday, taking cues from the global markets.

South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday.

Stocks To Watch Today, November 9: Reliance Industries, Cadila Healthcare, Britannia are in focus for today's trading session

Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.

Adani Ports has received go-ahead from the Competition Commission of India to acquire 10.40 per cent shareholding of Gangavaram Port

Wipro haslaunched the Wipro-Google Cloud Innovation Arena in Bangalore, Wipro said in a regulatory filing to the stock exchanges

ZyCoV-D is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

As part of the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium injection which Zydus Cadila will commercialize in the United States

Cadila Healthcare's total revenue from operations in the first quarter of the current fiscal stood at Rs 4,025.4 crore, compared to Rs 3,514.6 crore in the year-ago period

HDFC Bank, the country's largest private sector lender, has reported a 16.1 per cent year-on-year (YoY) rise in net profit at Rs 7,729.64 crore in the June quarter

Zydus Cadila has applied for Emergency Use Authorization to the office of Drug Controller General of India for ZyCoV-D - its Plasmid DNA vaccine against COVID-19

ONGC reported a jump in standalone net profit to Rs 6,733.97 crore in the quarter ended March 2021 from Rs 1,258.12 crore in the same quarter last year

Zydus Cadila Q4 FY21 Results: Cadila Healthcare reported a 73 per cent rise in consolidated net profit to Rs 679 crore in the January-March quarter of the financial year 2020-21.

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of

The domestic stock markets are expected to trade cautiously on Thursday, taking cues from the global markets.

South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday.

Stocks To Watch Today, November 9: Reliance Industries, Cadila Healthcare, Britannia are in focus for today's trading session

Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.

Adani Ports has received go-ahead from the Competition Commission of India to acquire 10.40 per cent shareholding of Gangavaram Port

Wipro haslaunched the Wipro-Google Cloud Innovation Arena in Bangalore, Wipro said in a regulatory filing to the stock exchanges

ZyCoV-D is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

As part of the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium injection which Zydus Cadila will commercialize in the United States

Cadila Healthcare's total revenue from operations in the first quarter of the current fiscal stood at Rs 4,025.4 crore, compared to Rs 3,514.6 crore in the year-ago period

HDFC Bank, the country's largest private sector lender, has reported a 16.1 per cent year-on-year (YoY) rise in net profit at Rs 7,729.64 crore in the June quarter

Zydus Cadila has applied for Emergency Use Authorization to the office of Drug Controller General of India for ZyCoV-D - its Plasmid DNA vaccine against COVID-19

ONGC reported a jump in standalone net profit to Rs 6,733.97 crore in the quarter ended March 2021 from Rs 1,258.12 crore in the same quarter last year

Zydus Cadila Q4 FY21 Results: Cadila Healthcare reported a 73 per cent rise in consolidated net profit to Rs 679 crore in the January-March quarter of the financial year 2020-21.